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The biosynthesis of human tumor necrosis factor (hTNF) was studied. The amino-termina1 extension of 
the hTNF precursor (26 kDa polypeptide) was not cleaved off in a cell-free system supplemented with dog 
pancreas microsomes. Correct maturation of pre-hTNF was nevertheless not restricted to the macrophage 
system: in the medium of a TNF-producing, transformed CHO ceil line, a (weak) N 20 kDa, an N 18.5 kDa 
(doublet) and a 17 kDa TNF poly~ptide, the latter corresponding to mature hTNF, were revealed by specific 
immunop~~ipitation. Similar results were obtained with Xenopus laevis oocytes, injected with hTNF 
mRNA, except hat the 20 kDa band was lacking. The results are discussed in relation to the secretion mech- 
anism of hTNF. 
1 v INTRODUCTION 
Human tumor necrosis factor (hTNF), a cyto- 
kine produced by macrophages, has been cloned 
by several groups [l-4). A comparison of its cDNA 
with the NHz-terminal end of the mature protein 
secreted by induced U937 cells [l] or HL60 cells 
[2,4] indicated that it is synthesized as a precursor 
with an NHz-terminal extension of 76 amino acids, 
while the mature product contains $57 amino acid 
residues [1,2&J. Although atypicailiy long, the pre- 
sequence contains a central, highly hydrophobic 
region (position - 46 to - 21 [ 1,2]) and resembles 
in this respect to so-called signal peptide of many 
other secretory proteins [5]. Noteworthy however 
is the presence of Lys-Lys and Arg-Arg sequences 
among the first 30 amino acid residues of the pre- 
sequence [l-4] which suggests that the NHz-termi- 
nal extension might p&haps be cleaved to peptides 
with special biological functions, since pairs of 
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basic amino acids are often targets for the reIease 
of such peptides 16-81. Here we report that the 
‘signal’ peptide of hTNF is not removed when its 
messenger RNA is translated in a cell-free system 
supplemented with dog pancreas microsomes, a 
phenomenon which sets it apart from many other 
secretory proteins [5]. We also show that the hTNF 
precursor can be properly matured in CHO eelis 
and Xenopecs faevis oocytes and that, consequent- 
fy, its special maturation is not restricted to the 
macrophage system. 
2. MATERIALS AND METHODS 
The information for almost the entire hTNF 
messenger RNA (from the F&I site at position 59 
to the DraI site at position 1511) was inserted into 
plasmid pSP65 (&omega-Biotech) in two steps. 
Plasmid pSP65 contains a promoter of Salvo- 
n&z phage SP6 and allows one, by means of SP6- 
RNA polymerase (~romega-Biotech~, to transcribe 
selectively any gene of interest in vitro [9]. The 
Published by EIsevier Science Publishers 3. V. (Biomedical Division) 
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cDNA clone phTNF1 [l] was first digested with 
FokI, and blunted by means of Klenow enzyme 
(Boehringer). The FokI fragment (blunted) from 
position 59 to 856 of the cDNA was purified and 
inserted into the SmaI site of pSP65. The orienta- 
tion of the insert was verified by restriction enzyme 
analysis. The resulting plasmid was consequently 
digested with Apa1 (position 228 of the hTNF 
cDNA) and NincII and ligated with the ApaI-DraI 
fragment of phTNF1 (position 228-1511 of the 
cDNA). The construction containing the cDNA in 
the correct orientation was designated pSP65- 
hTNF1 (fig. 1). 
m7(G5)ppp(5 ‘)G cap structure (Pharmacia PL-Bio- 
chemicals), 250,~M GTP and 500 PM of the 3 
other NTPs (Boehringer). After 1 h at 40°C the 
incubation mixture was phenol-chloroform ex- 
tracted and the newly synthesized RNA precipitat- 
ed with ethanol. No attempts were made to remove 
template DNA. The pellet was dissolved in Hz0 to 
a final concentration of approx. 100 pg RNA/ml. 
2.3. Translation in cell-free system supplemented 
Plasmid pSVd2-hTNF (PstI)-1 (fig. 1) contains 
the entire coding region of the hTNF gene as a PstI 
fragment originating from the cDNA clone 
phTNF1 [l]. Insertion was carried out by means of 
WI linkers into the unique San site of pSVdZ 
3tss+, a modified pSVd2 vector [lo]. The expres- 
sion unit of this vector consists of the SV40 early 
promoter, the Sun site, the SV40 small t-antigen 
splice donor and acceptor sites and the SV40 poly- 
adenylation site. 
with dog pancreas microsomes 
Cell-free translation was carried out using a rab- 
bit reticulocyte lysate (Amersham) and canine 
microsomal membranes (Amersham) essentially as 
recommended by the supplier. About 2-4~1 of in 
vitro synthesized capped transcript solution was 
used per 20~1 of lysate. A high specific activity 
[3H]amino acid mixture (TRK 550 Amersham) was 
used for labeling. Prior to the addition of Laemmli 
sample buffer [12], lysates were incubated with 
5 ,~l RNase A (200 pg/ml, Boehringer) for 15 min 
at 30°C. 
2.2. In vitro synthesis of capped transcripts 
Capped mRNA was synthesized in vitro as de- 
scribed by Contreras et al. [I 11. Plasmid pSP65- 
hTNF1 linearized at the unique NcoI site was used 
as a template for run-off transcription. In vitro 
transcription was carried out as recommended by 
the supplier (Promega-Biotech) except that the 
reaction mixture contained 0.5 A260 units of 
2.4. In vivo labeling of proteins 
CHO cells were cotransfected with pSVd2- 
hTNF1 (Pst)l and pAdD26 SV(A)-3 according to 
the method of Scahill et al. [ 131. TNF-producing 
colonies were subjected to methotrexate (10 mM) 
amplification [ 141 and assayed for TNF activity as 
described [151. For labeling, subcultures of a high 
producer cell line (approx. 10000 units/ml) were 
grown to confluency in medium (Gibco no. 
March 1986 
Fig.1. Plasmids pSP65-hTNF1 and pSVd2-hTNF (PstI)-1. Only relevant restriction sites are shown. The black bar 
represents hTNF cDNA information. The SP6 promoter and the SV40 early promoter are indicated by an open, large 
arrow. The SV40 small t splice region and polyadenylation segment are represented by a stippled and a hatched box, 
100 
respectively. AmpR, ampicillin resistance. 
Volume 197, number 1,2 FEBS LETTERS 
0722000) supplemented with 10% fetal calf serum. 
Cells were split the following day. Labeling was 
done overnight in medium containing 10% dia- 
lysed fetal calf serum, 50 &i/ml of a r4C-labeled 
amino acid mixture (Amersham) and 20-fold 
reduced amounts of unlabeled amino acids. 
X. laevis oocytes were injected with 50 nl of 
capped transcript solution (see above) per oocyte 
and incubated with 5 ~1 per oocyte of MBS 
(modified Barth solution) [16] supplemented with 
100 &i/ml of a 14C-amino acid mixture (Amer- 
sham) for 24 h at 18°C. 30 Kd- *s_ 
2.5. Immunoprecipitation 
Rabbit anti-hTNF serum (5 ~1) and supernatant 
(0.5 ml) were mixed and incubated on ice for 
2-3 h. For each pl of antiserum used, lOpI of a 
50% prewashed suspension of protein A- 
Sepharose (Pharmica) in phosphate-buffered 
saline (PBS) were added and the suspension was 
agitated gently at 4°C overnight. The beads were 
washed with several volumes of PBS containing 
0.05% Tween 80 and the antigen-antibody com- 
plexes were eluted with either sample buffer or 
Tris-SDS buffer according to Schwyzer et al. [17]. 
t - 
21SKd- .,# 
12.5Kd- 
2.6. Gel electrophoresis and autoradiography 
Samples were electrophoresed on 15% SDS- 
polyacrylamide slab gels [ 121. After staining (Serva 
blue R250) and destaining, gels were soaked in 
AmplifyTM (Amersham) or EnlightningTM (New 
England Nuclear) for 30-60 min, washed twice 
with water and dried. Autoradiography was done 
at - 70°C using Fuji X-ray film and intensifying 
screen. 
3. RESULTS 
3.1. Translation in cell-free system supplemen ted 
with dog pancreas microsomes 
In vitro synthesized, capped transcripts of hTNF 
were translated in a rabbit reticulocyte lysate in the 
presence and absence of dog pancreas microsomes 
as described in section 2. The results, shown in 
fig.2, can be summarized as follows: in the absence 
of microsomes (lane 2) a 26 kDa polypeptide can 
be detected, a size which is in agreement with that 
expected for the precursor. The presence of a faint, 
faster migrating band might possibly be ascribed to 
a second start of translation initiation in vitro [ 181: 
Fig.2. Translation products in a reticulocyte system in 
the presence and absence of dog pancreas microsomes. 
As described in section 2, in vitro synthesized, capped 
transcripts of the hTNF gene were translated in a rabbit 
reticulocyte lysate, all or not supplemented with dog 
pancreas microsomes. The ‘H-labeled translation 
products were electrophoresed on a 15% SDS-polyacryl- 
amide gel which was further processed for autoradiog- 
raphy. Lanes: 1, (r4C]methylated protein mixture 
(Amersham) [carbonic anhydrase (30 kDa), soybean 
trypsin inhibitor (21.5 kDa), cytochrome c (12.5 kDa), 
aprotinin (6.5 kDa), insulin chain B (3.4 kDa) and chain 
A (2.35 kDa)]; 2, translation products with TNF tran- 
script added but no microsomes; 3, control (no RNA, no 
microsomes added); 4, translation products obtained 
with TNF transcripts and microsomes added; 5, control 
(no RNA but microsomes present); 6, translation 
products in the presence of placental lactogen mRNA 
(Amersham) and no microsomes added; 7, as lane 6 but 
microsomes present. (b) Position of the 26 kDa hTNF 
precursor, (D) a faster moving product, presumably 
resulting from internal initiation (cf. text). 
indeed a second in-frame AUG is present only 5 
codons following the first one [l-4]. In the 
presence of microsomes (lane 4) no faster moving 
bands can be detected although human placental 
lactogen (lanes 6 and 7) was properly processed in 
this system. 
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Fig.3. Analysis of TNF-specific products secreted by 
CHO cells. TNF-producing CHO cells were labeled with 
a %-amino acid mixture for 19 h. The TNF related 
polypeptides were immunoprecipitated from the 
medium, analysed on a 15% SDS-polyacrylamide gel 
and the latter was processed for autoradiography as de- 
scribed in section 2. Lanes: 1, immunoprecipitate of the 
medium of 14C-labeled TNF-producing CHO ceils [cell 
line obtained by cotransfection with pSVd2-hTNF1 and 
pAdD26SV(A)-3~; 2, purified bacterially expressed 
mature hTNF Serva R250 stained (outlined in dashes); 3, 
control [immunoprecipitate from labeled CHO cells 
transfected with pSVd2 and pAdD26SV(A)-31; 4, [‘4C]- 
methylated protein mixture (Amersham) [myosin 
(200 kDa), phosphorylase b (92.5 kDa), bovine serum 
albumin (69 kDa), ovalbumin (46 kDa), carbonic 
anhydrase (30 kDa) and lysozyme (14.3 kDa)]. 
Fig.4. (a) Analysis of TNF-specific products secreted by medium of labeled oocytes injected with H20; 2, as lane 
X. luevis oocytes and by transfected CHO cells. X. faevis 1 but injected with in vitro synthesized capped tran- 
oocytes were injected, labeled and the bathing medium scripts of hTNF DNA; 3, immunoprecipitate of the 
immunoprecipitated as described in section 2. The im- medium of TNF-producing CHO cells (cf. fig.2) labeled 
munoprecipitate was loaded on a 15% SDS-polyacryl- with 14C-amino acids for 7 h; 4, as lane 3 but labeled for 
amide gel, which was further processed for autoradiog- 19 h. (b) Densitogram of the region of interest of lane 4, 
raphy. Lanes: 1, immunoprecipitate of the bathing panel a. The doublet nature of the - 18.5 kDa band is 
clearly revealed. 
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3.2. Translation in CHO cells 
CHO cells, transfected with pSVdZhTNF 
(PstI)-1, were labeled with a 14C-amino acid mix- 
ture and TNF released into the medium was im- 
munoprecipitated as described in section 2. Auto- 
radiography of the SDS-polyacrylamide gel re- 
vealed the presence of 4 polypeptides: one of 
20 kDa, a doublet at 18.5 kDa, and one of 17 kDa 
(fig.3, lane 1, see also fig.4b). The latter com- 
igrates with purified bacterially expressed hTNF 
(lane 2), which in turn comigrates with natural 
TNF from U937 cells [l]. The doublet nature of 
the 18.5 kDa band is usually in evidence on the 
original autoradiograph (see also below). 
3.3. Translation in X. laevis oocytes 
X. laevis oocytes were injected with capped tran- 
scripts of hTNF and labeled in vivo with a 14C- 
amino acid mixture as described in section 2. TNF 
in the bathing medium was immunoprecipitated 
and subjected to SDS-polyacrylamide gel electro- 
phoresis (see also section 2). 
As can be deduced from fig.4a, a pattern similar 
to that of the CHO cells was obtained except that 
the 20 kDa band was lacking (lane 2). 
4. DISCUSSION 
We have demonstrated that the signal peptide of 
hTNF is not cleaved in a cell-free translation 
system supplemented with dog pancreas micro- 
somes, a finding which sets TNF apart from the 
secreted proteins studied so far. Proteins such as 
e.g. ovalbumin, rhodopsin, rat cytochrome P-450 
and Sindbis envelope protein PE2, which are also 
not cleaved in an in vitro translation system, are 
apparently secreted in toto [19-221. 
The above finding, together with the presence of 
a hydrophobic region in the presequence which is 
long enough to span the membrane (i.e. 25 amino 
acid residues) suggests that TNF might be trans- 
ported as an integral membrane protein, the 
mature protein being released subsequently at a 
late stage of secretion, e.g. in the secretory vesicles 
or even at the cell surface. In this respect, the find- 
ing of a membrane bound IL1 activity, in addition 
to the secreted one 1231, might be relevant especial- 
ly inview of the fact that IL1 is also a macrophage 
product. Further studies are needed to follow the 
biosynthetic pathway of mature TNF. 
Our results however indicate that maturation of 
the TNF precursor is not restricted to the macro- 
phage system. In the supernatant of CHO cells, 
transfected with pSVdZhTNF (PstI)-1, as well as 
in the supernatant of X. laevis oocytes injected 
with capped TNF transcripts a polypeptide can be 
detected which comigrates with bacterially ex- 
pressed mature hTNF (fig.4a, lanes 2 and 3), which 
in turn comigrates with natural TNF from U937 
cells [I]. Furthermore, the pSVd2-hTNF (PstI)-1 
transfected CHO cells secrete a TNF biological ac- 
tivity of approx. 10000 units/ml, an activity which 
exceeds the one obtained with U937 cells after op- 
timum stimulation [24]. The biological activity ob- 
tained in the supernatant of X. laevis oocytes in- 
jected with in vitro synthesized capped transcripts 
is also relatively high (in the range of 500 
units/ml). Although precise quantitation is dif- 
ficult, it seems that the specific activity of the TNF 
produced by these non-macrophage systems is 
about the same as the one of natural TNF obtained 
from an induced macrophage cell line. So far, we 
have no precise knowledge about the nature of the 
slower migrating polypeptides which are also pre- 
sent in the supernatants (-20 kDa and 
- 18.5 kDa doublet for CHO cells, - 18.5 kDa 
doublet only for X. Iaevis oocytes). Several 
possibilities can be envisaged: either these polypep- 
tides are the result of secondary modification of 
the mature polypeptide or they represent inter- 
mediate precursor forms. Even a combination of 
both events cannot be excluded. The slower mov- 
ing polypeptides are clearly not due to N- 
glycosylation since they are resistant o concentra- 
tions of endoglycosidase F which are sufficient to 
deglycosylate interferon (not shown). This result is 
in agreement with the predicted amino acid se- 
quence for TNF [I] containing no potential N- 
glycosylation sites. Although not tested, we con- 
sider it very unlikely that they result from e.g. 
phosphorylation or acetylation since these 
modifications, unless very extensive, usually do 
not cause drastic changes in mobility. Never- 
theless, it is not excluded that at least one of the 
polypeptides of the - 18.5 kDa doublet might be 
due to some form of modification, for example O- 
glycosylation, since in the supernatant of induced 
U937 cells a faint 19 kDa polypeptide can be 
detected which has the same N-terminal amino 
acid sequence as the predominant 17 kDa TNF 
103 
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polypeptide (Smart, J. and Matt~iano, R. un- 
published). Only a thorough characterization of 
the slower moving bands will definitely establish 
whether 0-glycosylation has occurred and this 
might possibly shed more light on the mechanism 
of secretion also. A likely hypothesis is that at least 
one of the polypeptides of the 18.5 kDa doublet, 
and perhaps also the 20 kDa band, represent an in- 
termediate precursor form. The presence of 21 
amino acids between the end of the hydrophobic, 
presumably membrane-spanning, region in the 
presequence and the N-terminal end of the mature 
product supports this hypothesis of one or two in- 
termediate precursor forms being about 1.5 and/or 
3 kDa extended at the N-terminus. 
Some additional evidence for this possibility is 
provided by lymphotoxin of which two forms are 
identified: a so-called mature form and one having 
23 additional amino acids at the N-terminus (21. If 
similar results could be confirmed for TNF, the 
model of hTNF being transported as an integral 
membrane protein would definitely be strength- 
ened since the presence of immature forms in the 
supernatant could readily be explained by matura- 
tion at a late stage in the process. 
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